Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KRRO

Korro Bio Inc.

May 13 • 04:00PM ET

50.24

Dollar change -0.76
Percentage change -1.49	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DWAS AVSC

Index	-	P/E	-	EPS (ttm)	-63.36	Insider Own	42.35%	Shs Outstand	8.02M	Perf Week	-11.05%
Market Cap	402.92M	Forward P/E	-	EPS next Y	-8.87	Insider Trans	5.48%	Shs Float	4.63M	Perf Month	-33.00%
Income	-81.17M	PEG	-	EPS next Q	-2.38	Inst Own	59.07%	Short Float	2.68%	Perf Quarter	-8.65%
Sales	0.00M	P/S	-	EPS this Y	82.75%	Inst Trans	-28.25%	Short Ratio	3.54	Perf Half Y	22.18%
Book/sh	21.20	P/B	2.37	EPS next Y	3.18%	ROA	-47.34%	Short Interest	0.12M	Perf Year	438.33%
Cash/sh	21.16	P/C	2.37	EPS next 5Y	-	ROE	-67.90%	52W Range	4.57 - 97.91	Perf YTD	4.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.67%	ROI	-40.36%	52W High	-48.69%	Beta	3.96
Dividend TTM	-	Quick Ratio	8.87	Sales past 5Y	-26.84%	Gross Margin	-	52W Low	998.14%	ATR (14)	5.26
Dividend Ex-Date	-	Current Ratio	8.87	EPS Y/Y TTM	45.55%	Oper. Margin	0.00%	RSI (14)	34.56	Volatility	7.60% 8.69%
Employees	101	Debt/Eq	0.20	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	130.00
Option/Short	No / Yes	LT Debt/Eq	0.18	EPS Q/Q	80.13%	Payout	-	Rel Volume	1.45	Prev Close	51.00
Sales Surprise	-	EPS Surprise	-42.02%	Sales Q/Q	-	Earnings	Mar 26 AMC	Avg Volume	35.06K	Price	50.24
SMA20	-18.65%	SMA50	-22.80%	SMA200	28.21%	Trades		Volume	50,951	Change	-1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
09:55AM	Loading…
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Loading…
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire)
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
12:00PM	Loading…
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
09:09AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:50AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI (ACCESSWIRE)
03:27AM	Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-01-21 10:38AM	FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discuss Their Options (GlobeNewswire)
06:36AM	FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ (Newsfile)
Jul-30-21 08:49PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm (Business Wire)
07:19PM	Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (ACCESSWIRE)
05:15PM	FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
02:57PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
12:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT (ACCESSWIRE)
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ) (Business Wire)
11:30AM	CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	FREQ INVESTOR ALERT: Shareholder Lawsuit Deadline Approaching (ACCESSWIRE)
10:00AM	SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
10:00AM	FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (GlobeNewswire)
09:30AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
09:00AM	FREQUENCY THERAPEUTICS SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser (ACCESSWIRE)
05:18AM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)
Jul-29-21 08:47PM	Frequency Class Action Reminder (Newsfile)
05:29PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ (Newsfile)
04:02PM	MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ (PR Newswire)
01:15PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RLX and OTLY (ACCESSWIRE)
12:30PM	FREQ DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action FREQ (GlobeNewswire)
10:45AM	Lawsuits Filed Against FREQ, DIDI and OTLY - Jakubowitz Law Pursues Shareholders Claims (ACCESSWIRE)
10:00AM	FREQ Monday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
09:24AM	MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:27AM	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - (FREQ) (Newsfile)
Jul-28-21 08:00PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Frequency, Athira, Full Truck, and Coinbase and Encourages Investors to Contact the Firm (GlobeNewswire)
07:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (PR Newswire)
07:07PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
05:34PM	Frequency Shareholder Notice (Newsfile)
03:16PM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mathers Edward T	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
SANDELL SCOTT D	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Makhzoumi Mohamad	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Yang Rick	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Walker Paul Edward	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Florence Anthony A. Jr.	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Chang Carmen	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
BASKETT FOREST	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
New Enterprise Associates 17,	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Atlas Venture Opportunity Fund	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	195,074	Apr 23 05:23 PM
Lucchino David L.	Director	Nov 22 '23	Sale	37.69	1,156	43,573	22,150	Nov 27 08:48 PM
Lucchino David L.	Director	Nov 10 '23	Sale	41.97	968	40,632	23,306	Nov 22 04:05 PM
Lucchino David L.	President and CEO	Aug 18 '23	Sale	0.60	2,865	1,719	636,801	Aug 22 04:19 PM
Mitrano Richard J.	VP Finance & Operations	Aug 18 '23	Sale	0.63	227	143	48,694	Aug 22 04:21 PM
Lucchino David L.	President and CEO	Aug 17 '23	Sale	0.63	2,733	1,722	639,666	Aug 18 08:01 AM
Mitrano Richard J.	VP Finance & Operations	Aug 17 '23	Sale	0.62	230	143	48,921	Aug 18 08:05 AM
Lucchino David L.	President and CEO	Aug 16 '23	Sale	0.65	2,895	1,882	642,399	Aug 18 08:01 AM
Mitrano Richard J.	VP Finance & Operations	Aug 16 '23	Sale	0.67	234	157	49,151	Aug 18 08:05 AM
Lucchino David L.	President and CEO	Aug 15 '23	Sale	0.67	2,629	1,761	645,294	Aug 16 08:59 AM
Mitrano Richard J.	VP Finance & Operations	Aug 15 '23	Sale	0.65	228	148	49,385	Aug 16 09:02 AM
Lucchino David L.	President and CEO	Aug 14 '23	Sale	0.63	2,881	1,815	647,923	Aug 16 08:59 AM
Mitrano Richard J.	VP Finance & Operations	Aug 14 '23	Sale	0.64	238	152	49,613	Aug 16 09:02 AM
Lucchino David L.	President and CEO	Aug 11 '23	Sale	0.67	2,733	1,831	650,804	Aug 14 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Aug 11 '23	Sale	0.64	240	154	49,851	Aug 14 04:06 PM
Lucchino David L.	President and CEO	Aug 10 '23	Sale	0.68	2,790	1,897	653,537	Aug 14 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Aug 10 '23	Sale	0.64	247	158	50,091	Aug 14 04:06 PM
Lucchino David L.	President and CEO	Aug 09 '23	Sale	0.67	2,798	1,875	656,327	Aug 10 04:04 PM
Mitrano Richard J.	VP Finance & Operations	Aug 09 '23	Sale	0.66	238	157	50,338	Aug 10 04:02 PM
Lucchino David L.	President and CEO	Aug 08 '23	Sale	0.69	2,810	1,939	659,125	Aug 10 04:04 PM
Mitrano Richard J.	VP Finance & Operations	Aug 08 '23	Sale	0.67	241	161	50,576	Aug 10 04:02 PM
Lucchino David L.	President and CEO	Aug 07 '23	Sale	0.68	2,857	1,943	661,935	Aug 09 08:51 AM
Mitrano Richard J.	VP Finance & Operations	Aug 07 '23	Sale	0.69	235	162	50,817	Aug 09 08:50 AM
Lucchino David L.	President and CEO	Aug 04 '23	Sale	0.69	2,550	1,759	664,792	Aug 09 08:51 AM
Mitrano Richard J.	VP Finance & Operations	Aug 04 '23	Sale	0.67	220	147	51,052	Aug 09 08:50 AM
Lucchino David L.	President and CEO	Aug 03 '23	Sale	0.59	2,679	1,581	667,342	Aug 04 04:10 PM
Mitrano Richard J.	VP Finance & Operations	Aug 03 '23	Sale	0.56	232	130	51,272	Aug 04 04:09 PM
Lucchino David L.	President and CEO	Aug 02 '23	Sale	0.52	2,587	1,345	670,021	Aug 04 04:10 PM
Mitrano Richard J.	VP Finance & Operations	Aug 02 '23	Sale	0.49	231	113	51,504	Aug 04 04:09 PM
Lucchino David L.	President and CEO	Aug 01 '23	Sale	0.49	2,799	1,372	672,608	Aug 02 04:36 PM
Mitrano Richard J.	VP Finance & Operations	Aug 01 '23	Sale	0.48	238	114	51,735	Aug 02 04:35 PM
Lucchino David L.	President and CEO	Jul 31 '23	Sale	0.50	2,676	1,338	675,407	Aug 02 04:36 PM
Mitrano Richard J.	VP Finance & Operations	Jul 31 '23	Sale	0.50	222	111	51,973	Aug 02 04:35 PM
Lucchino David L.	President and CEO	Jul 28 '23	Sale	0.47	2,647	1,244	678,083	Jul 31 04:05 PM
Loose Christopher R.	Chief Scientific Officer	Jul 28 '23	Sale	0.46	1,344	618	183,650	Jul 31 04:01 PM
Mitrano Richard J.	VP Finance & Operations	Jul 28 '23	Sale	0.47	223	105	52,195	Jul 31 04:09 PM
Lucchino David L.	President and CEO	Jul 27 '23	Sale	0.51	2,791	1,423	680,730	Jul 31 04:05 PM
Loose Christopher R.	Chief Scientific Officer	Jul 27 '23	Sale	0.53	1,373	728	184,994	Jul 31 04:01 PM
Mitrano Richard J.	VP Finance & Operations	Jul 27 '23	Sale	0.53	227	120	52,418	Jul 31 04:09 PM
Lucchino David L.	President and CEO	Jul 26 '23	Sale	0.52	2,609	1,357	683,521	Jul 27 04:15 PM
Loose Christopher R.	Chief Scientific Officer	Jul 26 '23	Sale	0.51	1,329	678	186,367	Jul 27 04:16 PM
Mitrano Richard J.	VP Finance & Operations	Jul 26 '23	Sale	0.53	222	118	52,645	Jul 27 04:16 PM
Lucchino David L.	President and CEO	Jul 25 '23	Sale	0.50	2,803	1,402	686,130	Jul 27 04:15 PM
Loose Christopher R.	Chief Scientific Officer	Jul 25 '23	Sale	0.50	1,390	695	187,696	Jul 27 04:16 PM
Mitrano Richard J.	VP Finance & Operations	Jul 25 '23	Sale	0.50	234	117	52,867	Jul 27 04:16 PM
Lucchino David L.	President and CEO	Jul 24 '23	Sale	0.54	2,887	1,559	688,933	Jul 25 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 24 '23	Sale	0.54	1,438	777	189,086	Jul 25 04:56 PM
Mitrano Richard J.	VP Finance & Operations	Jul 24 '23	Sale	0.56	234	131	53,101	Jul 25 04:55 PM
Lucchino David L.	President and CEO	Jul 21 '23	Sale	0.61	2,663	1,624	691,820	Jul 25 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 21 '23	Sale	0.61	1,333	813	190,524	Jul 25 04:56 PM
Mitrano Richard J.	VP Finance & Operations	Jul 21 '23	Sale	0.61	223	136	53,335	Jul 25 04:55 PM
Lucchino David L.	President and CEO	Jul 20 '23	Sale	0.64	2,710	1,734	694,483	Jul 21 04:06 PM
Loose Christopher R.	Chief Scientific Officer	Jul 20 '23	Sale	0.64	1,361	871	191,857	Jul 21 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Jul 20 '23	Sale	0.64	229	147	53,558	Jul 21 04:04 PM
Lucchino David L.	President and CEO	Jul 19 '23	Sale	0.65	2,646	1,720	697,193	Jul 21 04:06 PM
Loose Christopher R.	Chief Scientific Officer	Jul 19 '23	Sale	0.65	1,335	868	193,218	Jul 21 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Jul 19 '23	Sale	0.63	228	144	53,787	Jul 21 04:04 PM
Lucchino David L.	President and CEO	Jul 18 '23	Sale	0.56	2,968	1,662	699,839	Jul 19 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 18 '23	Sale	0.56	1,484	831	194,553	Jul 19 04:13 PM
Mitrano Richard J.	VP Finance & Operations	Jul 18 '23	Sale	0.56	249	139	54,015	Jul 19 04:16 PM
Lucchino David L.	President and CEO	Jul 17 '23	Sale	0.68	2,775	1,887	702,807	Jul 19 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 17 '23	Sale	0.67	1,415	948	196,037	Jul 19 04:13 PM
Mitrano Richard J.	VP Finance & Operations	Jul 17 '23	Sale	0.65	244	159	54,264	Jul 19 04:16 PM
Lucchino David L.	President and CEO	Jul 14 '23	Sale	0.59	1,815	1,071	705,582	Jul 17 04:22 PM
Loose Christopher R.	Chief Scientific Officer	Jul 14 '23	Sale	0.59	906	535	197,452	Jul 17 04:23 PM
Mitrano Richard J.	VP Finance & Operations	Jul 14 '23	Sale	0.60	148	89	54,508	Jul 17 04:20 PM
Lucchino David L.	President and CEO	Jul 13 '23	Sale	0.39	2,646	1,032	707,397	Jul 17 04:22 PM
Loose Christopher R.	Chief Scientific Officer	Jul 13 '23	Sale	0.39	1,329	518	198,358	Jul 17 04:23 PM
Mitrano Richard J.	VP Finance & Operations	Jul 13 '23	Sale	0.39	227	89	54,656	Jul 17 04:20 PM
Lucchino David L.	President and CEO	Jul 12 '23	Sale	0.39	2,649	1,033	710,043	Jul 13 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 12 '23	Sale	0.39	1,335	521	199,687	Jul 13 04:42 PM
Mitrano Richard J.	VP Finance & Operations	Jul 12 '23	Sale	0.40	220	88	54,883	Jul 13 04:09 PM
Lucchino David L.	President and CEO	Jul 11 '23	Sale	0.37	2,731	1,010	712,692	Jul 13 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 11 '23	Sale	0.37	1,363	504	201,022	Jul 13 04:42 PM
Mitrano Richard J.	VP Finance & Operations	Jul 11 '23	Sale	0.37	228	84	55,103	Jul 13 04:09 PM
Lucchino David L.	President and CEO	Jul 10 '23	Sale	0.38	2,591	985	442,696	Jul 11 05:24 PM
Loose Christopher R.	Chief Scientific Officer	Jul 10 '23	Sale	0.37	1,304	482	66,023	Jul 11 05:35 PM
Mitrano Richard J.	VP Finance & Operations	Jul 10 '23	Sale	0.37	220	81	32,605	Jul 11 05:29 PM
Lucchino David L.	President and CEO	Jul 07 '23	Sale	0.35	2,634	922	436,196	Jul 11 05:24 PM
Loose Christopher R.	Chief Scientific Officer	Jul 07 '23	Sale	0.36	1,306	470	62,781	Jul 11 05:35 PM
Mitrano Richard J.	VP Finance & Operations	Jul 07 '23	Sale	0.36	220	79	32,067	Jul 11 05:29 PM
Lucchino David L.	President and CEO	Jul 06 '23	Sale	0.34	2,773	943	429,739	Jul 07 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 06 '23	Sale	0.34	1,384	471	57,758	Jul 07 04:54 PM
Mitrano Richard J.	VP Finance & Operations	Jul 06 '23	Sale	0.35	224	78	31,529	Jul 07 05:06 PM

Open in Screener

SVRA

Savara Inc

May 13 • 04:00PM ET

4.59

Dollar change -0.07
Percentage change -1.40	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO ONEQ IWC ITOT SBIO

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	51.14%	Shs Outstand	138.14M	Perf Week	-7.27%
Market Cap	634.25M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	-0.27%	Shs Float	67.52M	Perf Month	-9.47%
Income	-64.49M	PEG	-	EPS next Q	-0.11	Inst Own	42.84%	Short Float	6.37%	Perf Quarter	-8.20%
Sales	0.00M	P/S	-	EPS this Y	-25.54%	Inst Trans	2.91%	Short Ratio	4.72	Perf Half Y	34.60%
Book/sh	0.88	P/B	5.20	EPS next Y	-1.78%	ROA	-44.84%	Short Interest	4.30M	Perf Year	136.60%
Cash/sh	1.04	P/C	4.43	EPS next 5Y	-	ROE	-58.59%	52W Range	1.87 - 5.70	Perf YTD	-2.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.09%	ROI	-43.49%	52W High	-19.47%	Beta	0.73
Dividend TTM	-	Quick Ratio	14.90	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	145.45%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	14.90	EPS Y/Y TTM	-42.50%	Oper. Margin	0.00%	RSI (14)	45.46	Volatility	6.48% 6.30%
Employees	37	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.21
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	-61.22%	Payout	-	Rel Volume	0.77	Prev Close	4.66
Sales Surprise	-	EPS Surprise	-11.56%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	911.15K	Price	4.59
SMA20	-4.08%	SMA50	-6.07%	SMA200	7.93%	Trades		Volume	699,364	Change	-1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
10:54PM	Loading…
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-06-24 04:05PM	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-02-24 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-31-24 08:05AM	Savara to Present at Two Upcoming Healthcare Conferences (Business Wire)
Dec-30-23 03:01PM	Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) (GuruFocus.com)
Dec-21-23 08:05AM	Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Dec-20-23 08:05AM	Savara Added to the NASDAQ Biotechnology Index (Business Wire)
Dec-15-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-21-23 08:05AM	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
04:05PM	Loading…
Nov-09-23 04:05PM	Savara Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.84%
Nov-08-23 04:05PM	Savara to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-06-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-27-23 07:29PM	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade (InvestorPlace)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-05-23 04:05PM	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-10-23 04:05PM	Savara Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-04-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jul-13-23 07:00AM	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +8.92%
Jun-26-23 04:05PM	Savara Added to Russell 3000® Index (Business Wire) -7.34%
08:05AM	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-02-23 08:05AM	Savara to Present at the Jefferies Healthcare Conference (Business Wire)
May-28-23 08:26AM	Independent Director of Savara David Ramsay Buys 4.8% More Shares \ (Simply Wall St.)
May-16-23 12:32PM	Why Shares of Savara Jumped on Tuesday (Motley Fool) +9.09%
08:05AM	Loading…
May-15-23 08:05AM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-05-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +6.84%
Apr-03-23 07:33AM	Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near Future (Simply Wall St.) -6.15%
Mar-31-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-30-23 04:05PM	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Business Wire)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -7.31%
Mar-16-23 06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research)
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research) -15.94%
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 04:05PM	Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research) -7.42%
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 04:05PM	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research) +6.52%
06:24AM	Savara Inc. (NASDAQ:SVRA) insiders placed bullish bets worth US$858k in the last 12 months (Simply Wall St.)
Feb-14-23 08:05AM	Savara Announces New Leadership Appointments (Business Wire)
06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research)
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research) -5.16%
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research)
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research) -5.20%
Feb-01-23 06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)
Jan-31-23 06:50AM	Daily Vickers Top Insider Picks for 01/31/2023 (Argus Research)
Jan-30-23 06:42AM	Daily Vickers Top Insider Picks for 01/30/2023 (Argus Research)
Jan-27-23 03:47PM	Why Shares of Savara Soared This Week (Motley Fool)
07:00AM	Daily Vickers Top Insider Picks for 01/27/2023 (Argus Research)
Jan-26-23 06:44AM	Daily Vickers Top Insider Picks for 01/26/2023 (Argus Research)
Jan-25-23 06:39AM	Daily Vickers Top Insider Picks for 01/25/2023 (Argus Research) +8.02%
Jan-24-23 06:48AM	Daily Vickers Top Insider Picks for 01/24/2023 (Argus Research) +8.72%
Jan-23-23 06:58AM	Daily Vickers Top Insider Picks for 01/23/2023 (Argus Research)
Jan-20-23 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
06:55AM	Daily Vickers Top Insider Picks for 01/20/2023 (Argus Research)
Jan-19-23 06:43AM	Daily Vickers Top Insider Picks for 01/19/2023 (Argus Research)
Jan-18-23 06:28AM	Daily Vickers Top Insider Picks for 01/18/2023 (Argus Research)
Jan-17-23 06:27AM	Daily Vickers Top Insider Picks for 01/17/2023 (Argus Research)
Jan-13-23 06:56AM	Daily Vickers Top Insider Picks for 01/13/2023 (Argus Research)
Jan-12-23 06:50AM	Daily Vickers Top Insider Picks for 01/12/2023 (Argus Research)
Jan-11-23 06:53AM	Daily Vickers Top Insider Picks for 01/11/2023 (Argus Research)
Jan-09-23 06:31AM	Daily Vickers Top Insider Picks for 01/09/2023 (Argus Research)
Jan-06-23 06:49AM	Daily Vickers Top Insider Picks for 01/06/2023 (Argus Research)
Jan-05-23 05:43AM	Private equity firms are Savara Inc.'s (NASDAQ:SVRA) biggest owners and were rewarded after market cap rose by US$25m last week (Simply Wall St.)
Jan-04-23 06:54AM	Daily Vickers Top Insider Picks for 01/04/2023 (Argus Research) +9.38%
06:54AM	Daily Vickers Top Buyers & Sellers for 01/04/2023 (Argus Research)
Jan-03-23 06:26AM	Daily Vickers Top Insider Picks for 01/03/2023 (Argus Research)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research)
Dec-29-22 06:51AM	Daily Vickers Top Insider Picks for 12/29/2022 (Argus Research)
Dec-27-22 07:11AM	Daily Vickers Top Insider Picks for 12/27/2022 (Argus Research)
Dec-23-22 06:32AM	Daily Vickers Top Insider Picks for 12/23/2022 (Argus Research)
Nov-22-22 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-10-22 04:05PM	Savara Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-09-22 04:05PM	Savara to Participate in Three Upcoming Investor Conferences (Business Wire)
Sep-14-22 04:05PM	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elam Nevan C	Director	Dec 28 '23	Option Exercise	1.30	53,758	69,722	116,343	Dec 29 04:33 PM
Elam Nevan C	Director	Dec 28 '23	Sale	4.71	93,843	442,291	22,500	Dec 29 04:33 PM
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 28 '23	Sale	4.71	84,000	395,900	1,302,674	Dec 29 04:35 PM
Lowrance David L	CHIEF FINANCIAL OFFICER	Dec 28 '23	Sale	4.71	10,000	47,131	342,355	Dec 29 04:34 PM
Hawkins Richard J	Director	Dec 11 '23	Option Exercise	0.82	10,841	8,890	12,741	Dec 12 06:09 PM
Elam Nevan C	Director	Dec 11 '23	Option Exercise	0.82	10,841	8,890	40,085	Dec 12 06:08 PM
Chang Carmen	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:07 PM
Behbahani Ali	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:06 PM
BASKETT FOREST	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:05 PM
Growth Equity Opportunities 17	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:04 PM
Yang Rick	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:13 PM
SANDELL SCOTT D	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:11 PM
Walker Paul Edward	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:12 PM
Mathers Edward T	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:10 PM
Makhzoumi Mohamad	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:09 PM
Florence Anthony A. Jr.	10% Owner	Jul 17 '23	Buy	3.00	333,333	999,999	24,471,264	Jul 19 07:08 PM
Pratt Raymond Dennis	Chief Medical Officer	Jun 26 '23	Buy	2.93	6,500	19,045	160,000	Jun 27 07:00 AM
RAMSAY DAVID A	Director	May 26 '23	Buy	2.63	37,124	97,599	2,201,142	May 26 11:31 AM
RAMSAY DAVID A	Director	May 25 '23	Buy	2.57	12,876	33,130	2,164,018	May 26 11:31 AM
RAMSAY DAVID A	Director	May 24 '23	Buy	2.56	50,000	127,800	2,151,142	May 26 11:31 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

KRRO

Korro Bio Inc.

SVRA

Savara Inc

Upgrade your FINVIZ experience